

FOR IMMEDIATE RELEASE

OmniComm Systems[®] Recognizes Excellence in Clinical Research and Development at Innovation Forum 2014

Industry leaders convene to demonstrate the transformative effect of OmniComm technology

Fort Lauderdale, FL, December 19, 2014 - OmniComm Systems, Inc., (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, recognizes excellence in innovation at OmniComm's 4th annual Innovation Forum customer summit.

The two-day event provided a forum for OmniComm customers to network, share current innovations, best practices and demonstrate the transformative impact of OmniComm's technology on clinical development and research. Customer attendance was up by more than 40% over last year; comprising over 30 life science companies and partners.

Attendees heard from over 12 OmniComm customer and partner speakers, who achieved significant gains in clinical trial productivity, clinic automation, clinical data quality, operational efficiency and compliance. Attendees participated in over 25 sessions and had access to over 15 hours of keynotes, presentations, and panel discussions during the two day event.

"We are humbled by the great turnout at our 4th annual Innovation Forum that brings our customers, industry thought leaders and partners together to share lessons learned and discuss the business impact of our innovative technologies," said Stephen Johnson, president and COO of OmniComm Systems, Inc. "This year a vast number of companies adopted OmniComm technology and the Innovation Forum is the ideal venue for collaboration and the exchange of ideas. We look forward to working with all of customers in shaping the industry narrative."

Innovation Forum Highlights:

- The Innovation Forum's theme of creating value through innovation was echoed in the keynote address by Rob Petrie, Vice President, Information Technology, for PPD.
- Attendees heard how TrialMaster EDC technology was pivotal in demonstrating improved quality-of-life for post myocardial infarction diabetes patients. The Trial to Assess Chelation Therapy (TACT) lasted 8 years, involved 130 clinics with over 1700 patients. Gervasio Lamas, MD, Chairman of Medicine, Mount Sinai Medical Center of Miami presented the results.
- Sarah Cannon Research Institute (SCRI) received the Excellence in Innovation award. SCRI, along with OmniComm, implemented a seamless integration between TrialMaster and a leading third party clinical trial management system (CTMS), resulting in elimination of duplicate data, improved data consistency and a comprehensive view of the clinical trial.



 A global, top 5, pharmaceutical company received an Excellence in Innovation Award for their leadership in Phase I clinic automation utilizing TrialOne[®], inspiring the implementation of a host of capabilities that improve the overall efficiency, data quality and patient safety within their Phase I clinic.

About OmniComm Systems, Inc.

OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world's pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit <u>www.omnicomm.com</u>.

Trademarks

OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

Contact Info

Dennis Constantinou OmniComm Systems, Inc. +1.954.473.1254 dconstantinou@omnicomm.com